Effectiveness of Ethinylestradiol/Chlormadinone Acetate in Treating Dermatological Conditions Related to High Androgen Levels

September 2011 in “ American Journal of Clinical Dermatology ”

A. Guerra‐Tapia, Blanca Sancho Pérez

ethinylestradiol chlormadinone acetate oral contraceptive acne vulgaris hirsutism seborrhea female pattern hair loss hyperandrogenemia EE/CMA acne FPHL

Studysummary This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

research Efficacy of an Oral Contraceptive Containing EE 0.03 mg and CMA 2 mg (Belara) in Moderate Acne Resolution: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

42 citations , May 2009 in “Contraception”

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

research Management of Androgenetic Alopecia in Postmenopausal Women

15 citations , May 2008 in “Actas Dermo-Sifiliográficas”

This review discusses different clinical forms, laboratory tests, and treatments for female androgenetic alopecia and reports no new results; it emphasizes the importance of proper management.

research Effects of Two Estroprogestins Containing Ethinylestradiol 30 μg and Drospirenone 3 mg and Ethinylestradiol 30 μg and Chlormadinone 2 mg on Skin and Hormonal Hyperandrogenic Manifestations

31 citations , January 2008 in “Gynecological endocrinology”

In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.

research Managing Cutaneous Manifestations of Hyperandrogenic Disorders

22 citations , January 2002 in “Treatments in endocrinology”

This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.

research Acne

81 citations , January 2002 in “American journal of clinical dermatology”

Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.

research Acne Resolution Rates: Results of a Single-Blind, Randomized, Controlled, Parallel Phase III Trial with EE/CMA (Belara®) and EE/LNG (Microgynon®)

88 citations , January 2001 in “Dermatology”

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

Incidence of Female Androgenetic Alopecia (Female Pattern Alopecia)

research Outcome of Long-Term Treatment with the 5α-Reductase Inhibitor Finasteride in Idiopathic Hirsutism: Clinical and Hormonal Effects During a 1-Year Course of Therapy and 1-Year Follow-Up

75 citations , November 1996 in “Fertility and Sterility”

This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.